Last reviewed · How we verify
OMVOH (MIRIKIZUMAB-MRKZ)
OMVOH (generic name: MIRIKIZUMAB-MRKZ) is a Interleukin-23 Antagonist [EPC] drug developed by ELI LILLY AND CO. It is currently FDA-approved for Moderately to severely active ulcerative colitis.
Mirikizumab is an interleukin-23 inhibitor, classified as an antibody, used to treat conditions such as Ulcerative Colitis, Pouchitis, and Crohn's Disease. It is administered via intravenous or subcutaneous routes, and its effectiveness is being studied in real-world settings through the MIRROR registry.
At a glance
| Generic name | MIRIKIZUMAB-MRKZ |
|---|---|
| Sponsor | ELI LILLY AND CO |
| Drug class | Interleukin-23 Antagonist [EPC] |
| Target | Interleukin-23 subunit alpha |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Moderately to severely active ulcerative colitis
Common side effects
- Infections
- Upper respiratory tract infections
- Injection site reactions
- Rash
- Herpes viral infection
Serious adverse events
- Serious infections
- Intestinal sepsis
- Listeria sepsis
- Pneumonia
- COVID-19 pneumonia
- Infusion-related hypersensitivity reactions
- Alanine aminotransferase (ALT) ≥5X ULN
- Aspartate aminotransferase (AST) ≥5X ULN
Key clinical trials
- VOICE-Characterization of Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease Using Patient-Reported Outcome Measures: A Prospective Observational Study (N/A)
- An Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to Crohn's Disease (Phase 4)
- MIrikizumab in UC - a Real-woRld prOspective multicenteR Registry (N/A)
- Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch (Phase 4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OMVOH CI brief — competitive landscape report
- OMVOH updates RSS · CI watch RSS
- ELI LILLY AND CO portfolio CI
Frequently asked questions about OMVOH
What is OMVOH?
What is OMVOH used for?
Who makes OMVOH?
What is the generic name of OMVOH?
What drug class is OMVOH in?
What development phase is OMVOH in?
What are the side effects of OMVOH?
What does OMVOH target?
Related
- Drug class: All Interleukin-23 Antagonist [EPC] drugs
- Target: All drugs targeting Interleukin-23 subunit alpha
- Manufacturer: ELI LILLY AND CO — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Moderately to severely active ulcerative colitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing